{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:18:47Z","timestamp":1790965127230,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004597","name":"University of Kalyani","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004597","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"ICMR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.lfs.2024.122844","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:22:19Z","timestamp":1718623339000},"page":"122844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Repurposing approved protein kinase inhibitors as potent anti-leishmanials targeting Leishmania MAP kinases"],"prefix":"10.1016","volume":"351","author":[{"given":"Anindita","family":"Bhattacharjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arka","family":"Bagchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solanki","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriparna","family":"Bawali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunima","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.122844_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.00184","article-title":"Role of protein phosphorylation in the regulation of cell cycle and DNA-related processes in bacteria","volume":"7","author":"Garcia-Garcia","year":"2016","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122844_bb0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/microorganisms9040691","article-title":"Leishmania protein kinases: important regulators of the parasite life cycle and molecular targets for treating leishmaniasis","volume":"9","author":"Efstathiou","year":"2021","journal-title":"Microorganisms"},{"issue":"7","key":"10.1016\/j.lfs.2024.122844_bb0015","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.90.7.2656","article-title":"Protein kinases in divergent eukaryotes: identification of protein kinase activities regulated during trypanosome development","volume":"90","author":"Parsons","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.lfs.2024.122844_bb0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0166-6851(91)90091-J","article-title":"Distinct patterns of tyrosine phosphorylation during the life cycle of Trypanosoma brucei","volume":"45","author":"Parsons","year":"1991","journal-title":"Mol. Biochem. Parasitol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122844_bb0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1550-7408.1992.tb01473.x","article-title":"Evidence of tyrosine kinase activity in the protozoan parasite Trypanosoma brucei","volume":"39","author":"Wheeler-Alm","year":"1992","journal-title":"J. Protozool."},{"issue":"13","key":"10.1016\/j.lfs.2024.122844_bb0030","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1002\/pmic.200800874","article-title":"Phosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stage","volume":"9","author":"Nakayasu","year":"2009","journal-title":"Proteomics"},{"key":"10.1016\/j.lfs.2024.122844_bb0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1471-2164-6-127","article-title":"Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi","volume":"6","author":"Parsons","year":"2005","journal-title":"BMC Genomics"},{"issue":"10","key":"10.1016\/j.lfs.2024.122844_bb0040","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ijpara.2007.04.008","article-title":"Leishmania MAP kinases \u2013 familiar proteins in an unusual context","volume":"37","author":"Wiese","year":"2007","journal-title":"Int. J. Parasitol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122844_bb0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1128\/EC.2.4.769-777.2003","article-title":"Protein kinase involved in flagellar-length control","volume":"2","author":"Wiese","year":"2003","journal-title":"Eukaryot. Cell"},{"issue":"5","key":"10.1016\/j.lfs.2024.122844_bb0050","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/j.1365-2958.2005.04498.x","article-title":"LmxMPK9, a mitogen-activated protein kinase homologue affects flagellar length in Leishmania mexicana","volume":"55","author":"Bengs","year":"2005","journal-title":"Mol. Microbiol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122844_bb0055","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1365-2958.2005.04614.x","article-title":"LmxPK4, a mitogen-activated protein kinase kinase homologue of Leishmania mexicana with a potential role in parasite differentiation","volume":"56","author":"Kuhn","year":"2005","journal-title":"Mol. Microbiol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122844_bb0060","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1091\/mbc.e05-10-0976","article-title":"Interacting protein kinases involved in the regulation of flagellar length","volume":"17","author":"Erdmann","year":"2006","journal-title":"Mol. Biol. Cell"},{"issue":"9","key":"10.1016\/j.lfs.2024.122844_bb0065","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/emboj\/17.9.2619","article-title":"A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host","volume":"17","author":"Wiese","year":"1998","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.lfs.2024.122844_bb0070","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.ijpara.2007.03.006","article-title":"Over-expression of Leishmania major MAP kinases reveals stage-specific induction of phosphotransferase activity","volume":"37","author":"Morales","year":"2007","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.lfs.2024.122844_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2024.122844_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/0471142727.mb2806s111","article-title":"Assaying cell cycle status using flow cytometry","volume":"111","author":"Kim","year":"2015","journal-title":"Curr. Protoc. Mol. Biol."},{"issue":"8","key":"10.1016\/j.lfs.2024.122844_bb0085","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00203-022-03107-1","article-title":"Evolutionary analysis of globin domains from kinetoplastids","volume":"204","author":"Mitra","year":"2022","journal-title":"Arch. Microbiol."},{"issue":"13","key":"10.1016\/j.lfs.2024.122844_bb0090","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1093\/nar\/gkg520","article-title":"SWISS-MODEL: an automated protein homology-modeling server","volume":"31","author":"Schwede","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2024.122844_bb0095","article-title":"Comparative protein structure modeling using modeller","volume":"0 5","author":"Eswar","year":"2006","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"10.1016\/j.lfs.2024.122844_bb0100","first-page":"33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Chem."},{"issue":"4","key":"10.1016\/j.lfs.2024.122844_bb0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00203-023-03463-6","article-title":"In silico evolutionary and structural analysis of cAMP response proteins (CARPs) from Leishmania major","volume":"205","author":"Bhakta","year":"2023","journal-title":"Arch. Microbiol."},{"issue":"W1","key":"10.1016\/j.lfs.2024.122844_bb0110","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2024.122844_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.lfs.2024.122844_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004347","article-title":"Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability","volume":"10","author":"Cayla","year":"2014","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.lfs.2024.122844_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ceb.2009.01.015","article-title":"Targeting protein kinases for the development of anti-inflammatory drugs","volume":"21","author":"Cohen","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122844_bb0130","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-07-4790","article-title":"Advances in targeting the Ras\/Raf\/MEK\/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy","volume":"14","author":"Friday","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lfs.2024.122844_bb0135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/ml4000063","article-title":"Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors","volume":"4","author":"Rheault","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.lfs.2024.122844_bb0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.14348\/molcells.2016.2300","article-title":"A receptor tyrosine kinase inhibitor, dovitinib (TKI-258), enhances BMP-2-induced osteoblast differentiation in vitro","volume":"39","author":"Lee","year":"2016","journal-title":"Mol. Cell"},{"issue":"13","key":"10.1016\/j.lfs.2024.122844_bb0145","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: first global approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.lfs.2024.122844_bb0150","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.3390\/molecules26216677","article-title":"Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2024.122844_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3268136","article-title":"Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits","volume":"2021","author":"Sharifi-Rad","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2024.122844_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton\u2019s tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.lfs.2024.122844_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.lfs.2024.122844_bb0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1358\/dot.2006.42.7.985637","article-title":"Lapatinib: a novel EGFR\/HER2 tyrosine kinase inhibitor for cancer","volume":"42","author":"Johnston","year":"2006","journal-title":"Drugs Today (Barc.)"},{"issue":"4","key":"10.1016\/j.lfs.2024.122844_bb0175","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","article-title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background","volume":"11","author":"Davies","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.lfs.2024.122844_bb0180","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/annonc\/mdw320","volume":"27","author":"Vuylsteke","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2024.122844_bb0185","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"Onco. Targets Ther."},{"issue":"10","key":"10.1016\/j.lfs.2024.122844_bb0190","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2024.122844_bb0195","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-11-4","article-title":"Tofacitinib and newer JAK inhibitors in inflammatory bowel disease\u2014where we are and where we are going","volume":"11","author":"Liu","year":"2022","journal-title":"Drugs Context"},{"key":"10.1016\/j.lfs.2024.122844_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.122844_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fitd.2022.837460","article-title":"Tackling drug resistance and other causes of treatment failure in leishmaniasis","volume":"3","author":"Wijnant","year":"2022","journal-title":"Front. Trop. Dis."},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41579-022-00777-y","article-title":"Anti-trypanosomatid drug discovery: progress and challenges","volume":"21","author":"De Rycker","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"7717","key":"10.1016\/j.lfs.2024.122844_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.lfs.2024.122844_bb0220","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1073\/pnas.1820175116","article-title":"Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition","volume":"116","author":"Wyllie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.lfs.2024.122844_bb0225","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1021\/acs.jmedchem.1c00047","article-title":"Scaffold-hopping strategy on a series of proteasome inhibitors led to a preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Thomas","year":"2021","journal-title":"J. Med. Chem."},{"issue":"7619","key":"10.1016\/j.lfs.2024.122844_bb0230","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.lfs.2024.122844_bb0235","doi-asserted-by":"crossref","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","article-title":"DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Mowbray","year":"2021","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.lfs.2024.122844_bb0240","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00829-19","article-title":"Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis","volume":"63","author":"Wijnant","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5733","key":"10.1016\/j.lfs.2024.122844_bb0245","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1126\/science.1112642","article-title":"The genome of the African trypanosome Trypanosoma brucei","volume":"309","author":"Berriman","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.lfs.2024.122844_bb0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0974-777X.62886","article-title":"Liposomal amphotericin B and leishmaniasis: dose and response","volume":"2","author":"Sundar","year":"2010","journal-title":"J. Global Infect. Dis."},{"key":"10.1016\/j.lfs.2024.122844_bb0255","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejmech.2017.04.044","article-title":"An overview of azoles targeting sterol 14\u03b1-demethylase for antileishmanial therapy","volume":"135","author":"Emami","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.lfs.2024.122844_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007253","article-title":"Topical paromomycin for New World cutaneous leishmaniasis","volume":"13","author":"Sosa","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0265","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/pharmaceutics15010099","article-title":"Liposomal amphotericin B for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations","volume":"15","author":"Fr\u00e9zard","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.lfs.2024.122844_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101128","article-title":"New strategies for targeting kinase networks in cancer","volume":"297","author":"Yesilkanal","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.122844_bb0275","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.lfs.2024.122844_bb0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0285","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0290","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-022-00788-0","article-title":"Novel FLT3\/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma","volume":"29","author":"Lai","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.lfs.2024.122844_bb0295","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ebiom.2018.10.016","article-title":"New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates","volume":"37","author":"Bhattacharya","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lfs.2024.122844_bb0300","article-title":"Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival","author":"N","year":"2020","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0305","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41467-019-13344-6","article-title":"Coupling chemical mutagenesis to next generation sequencing for the identification of drug resistance mutations in Leishmania","volume":"10","author":"Bhattacharya","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.lfs.2024.122844_bb0310","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/mmi.13375","article-title":"Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in Leishmania mexicana cell cycle regulation","volume":"100","author":"Duncan","year":"2016","journal-title":"Mol. Microbiol."},{"issue":"6","key":"10.1016\/j.lfs.2024.122844_bb0315","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1365-2958.2012.08169.x","article-title":"Modulation of Leishmania major aquaglyceroporin activity by a mitogen-activated protein kinase","volume":"85","author":"Mandal","year":"2012","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.lfs.2024.122844_bb0320","doi-asserted-by":"crossref","DOI":"10.1038\/srep30832","article-title":"Imatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategy","volume":"6","author":"Tsutsui","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.lfs.2024.122844_bb0325","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3934\/microbiol.2020010","article-title":"Study of therapeutic effect of different concentrations of imatinib on Balb\/c model of cutaneous leishmaniasis","volume":"6","author":"Moslehi","year":"2020","journal-title":"AIMS Microbiol."},{"key":"10.1016\/j.lfs.2024.122844_bb0330","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasit. Vectors"},{"issue":"8","key":"10.1016\/j.lfs.2024.122844_bb0335","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2007.04.016","article-title":"Modulation of T-effector function by imatinib at the level of cytokine secretion","volume":"35","author":"Leder","year":"2007","journal-title":"Exp. Hematol."},{"issue":"11","key":"10.1016\/j.lfs.2024.122844_bb0340","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.leu.2403933","article-title":"Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia","volume":"19","author":"Gao","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0345","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41420-022-01073-7","article-title":"Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB\/AP-1 pathway and TLR4 expression","volume":"8","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0350","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1186\/s12885-017-3889-x","article-title":"Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study","volume":"17","author":"Hayashi","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2024.122844_bb0355","first-page":"315","article-title":"Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase","volume":"4","author":"Mughal","year":"2010","journal-title":"Biologics"},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0360","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.lfs.2024.122844_bb0365","doi-asserted-by":"crossref","first-page":"470","DOI":"10.5581\/1516-8484.20110124","article-title":"Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia","volume":"33","author":"Bitencourt","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"1","key":"10.1016\/j.lfs.2024.122844_bb0370","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.lfs.2024.122844_bb0375","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jac\/dkv495","article-title":"Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis","volume":"71","author":"Trinconi","year":"2016","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052400434X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052400434X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T19:56:22Z","timestamp":1732218982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432052400434X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":75,"alternative-id":["S002432052400434X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122844","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.16.580710","asserted-by":"object"}]},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing approved protein kinase inhibitors as potent anti-leishmanials targeting Leishmania MAP kinases","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122844"}}